Source: International Congress 2019 – Genes and environment
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
T. Beiko (Charleston, United States of America), D. Woodford (Charleston, United States of America), C. Strange (Charleston, United States of America). Anxiety in a population tested for alpha-1 antitrypsin deficiency.. 5399

Member's Comments

No comment yet.

Related content which might interest you: Prevalence of alpha-1 antitrypsin deficiency (AATD) in Greater Glasgow and Clyde (GG&C) and current practises Source: Virtual Congress 2020 – COPD phenotypes Year: 2020 Diagnosing alpha-1 antitrypsin deficiency in Romania - first 1000 cases tested Source: Virtual Congress 2020 – Asthma and COPD: How genetic and environment influences its developement? Year: 2020 Alpha-1 antitrypsin deficiency severity and the risk of COVID-19 Source: Virtual Congress 2021 – Burden and epidemiology of COVID-19 Year: 2021 Alpha 1 antitrypsin (A1AT) deficiency in children with asthma in Brazil Source: Eur Respir J 2003; 22: Suppl. 45, 499s Year: 2003 Reduction in incidence of exacerbations in patients with alpha 1 antitrypsin deficiency (A1ATD) treated with concentrates of alpha 1 antitrypsin (A1AT): REXA study Source: Annual Congress 2011 - Biomarkers and exacerbations of asthma and COPD Year: 2011 Rare alpha-1 antitrypsin mutations in the Irish population Source: Annual Congress 2011 - Genetic and environmental risk factors for respiratory diseases Year: 2011 Rare alpha-1 antitrypsin mutations in the Irish population Source: Annual Congress 2012 - COPD inflammation and genes Year: 2012 Pilot study for detection of alpha-1 antitrypsin deficiency in a targeted Argentinean population Source: Eur Respir J 2005; 26: Suppl. 49, 59s Year: 2005 Regional deposition of 99mTc-labelled alpha-1 antitrypsin (AAT) in patients with alpha-1 antitrypsin deficiency and cystic fibrosis (CF) compared with healthy volunteers Source: Annual Congress 2007 - Cystic fibrosis: the balance between treatment and side-effects Year: 2007 Implementation of screening program for alpha-1 antitrypsin deficiency in Spain Source: Annual Congress 2004 - Emphysema and oxygen therapy Year: 2004 Screening for alpha-1 antitrypsin deficiency in Polish lung or liver disease patients Source: Annual Congress 2011 - Lung development and neoplasia Year: 2011 Clinical features of alpha one antitrypsin deficiency in COPD Source: Annual Congress 2012 - Inflammation in airway diseases: diagnosis and management Year: 2012 Molecular characterization of novel PiS-like alleles identified in Spanish patients with Alpha-1 antitrypsin deficiency Source: International Congress 2018 – Functional genomics and COPD: new challenges Year: 2018 Characterisation of alpha-1 antitrypsin protein expression and secretion in natural killer cells from healthy volunteers and alpha-1 antitrypsin deficiency patients Source: Virtual Congress 2021 – Novel insights into the pathogenesis of chronic lung diseases Year: 2021 Alpha-1 antitrypsin: functional analysis of novel variants Source: Research Seminar 2014 - Protein quality control in lung disease Year: 2014 Trends in diagnosis and clinical presentation of alpha-1 antitrypsin deficiency within an Irish population Source: Annual Congress 2012 - Inflammation in airway diseases: diagnosis and management Year: 2012 Relationship between atopy, asthma and alpha-1 antitrypsin deficiency Source: International Congress 2019 – Clinical aspects of airway diseases Year: 2019